CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Clinical trial NCT03795779 · UNKNOWN

Trial details

NCT number: NCT03795779
Sponsor: iCell Gene Therapeutics
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Hematologic Malignancy Acute Myeloid Leukemia Myelodysplastic Syndromes Myeloproliferative Neoplasm Chronic Myeloid Leukemia

Start date: 2018-03-01
Primary completion: 2022-09-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.